Opus Genetics logo

Opus Genetics (IRD) Q1 2026 Earnings

IRD·Reported May 12, 2026·Before market open

Opus Genetics reported Q1 2026 revenue of $2.2M (-50.6% YoY), missed analyst consensus of $2.9M by $771.1K. Diluted EPS came in at $-0.75 (-134.4% YoY), missed the $-0.16 consensus by $0.59.

Revenue
$2.2Mmissed by $771.1K
Consensus: $2.9M
Diluted EPS
$-0.75missed by $0.59
Consensus: $-0.16
SEC

SEC Filings

Earnings release8-K · 0001628280-26-033856
Quarterly report10-Q · 0001628280-26-034084

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Opus Genetics's Q1 2026 earnings report.

Opus Genetics (IRD) reported Q1 2026 earnings on May 12, 2026 before market open.

Opus Genetics reported revenue of $2.2M and diluted EPS of $-0.75 for Q1 2026.

Revenue missed the consensus estimate of $2.9M by $771.1K. EPS missed the consensus estimate of $-0.16 by $0.59.

Compared to the same quarter a year prior, revenue declined 50.6% from $4.4M a year earlier and diluted EPS declined 134.4% from $-0.32.

You can read the 8-K earnings release (0001628280-26-033856) and the 10-Q periodic report (0001628280-26-034084) directly on SEC EDGAR. The filing index links above go to sec.gov.